Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile

This article was originally published in The Pink Sheet Daily

Executive Summary

Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx’s Nexavar .

You may also be interested in...



Aveo’s Tivozanib Will Face Challenging Survival Data At ODAC Review

FDA’s Oncologic Drugs Advisory Committee will consider the tyrosine kinase inhibitor for advanced renal cell carcinoma at a May 2 meeting. Aveo has attributed a negative overall survival trend in the TIVO-1 study to a crossover design and use of post-progression therapies among patients randomized to the comparator arm.

Germany’s IQWiG: New Year, Same Sternness On Dossier Structure

Pfizer’s kidney cancer drug Inlyta scrapes through the German added value assessment process but Almirall’s COPD product Eklira gets a “thumbs down,” showing that comparator selection is not the only deciding factor in the process.

Vertex's Cystic Fibrosis Drug Kalydeco Given Green Light By EU's Scientific Advisory Panel

Vertex's cystic fibrosis product Kalydeco is one of five new molecular entities given a positive opinion by Europe's Committee for Medicinal Products for Human Use on May 25, which also included Almirall's novel COPD therapy aclidinium and Novo Nordisk's recombinant Factor XIII.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel